Sarah P Hudson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5610765/publications.pdf

Version: 2024-02-01

50 2,206 19 47
papers citations h-index g-index

52 52 52 3471 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Proteins in Mesoporous Silicates. Angewandte Chemie - International Edition, 2008, 47, 8582-8594.	7.2	622
2	The biocompatibility of mesoporous silicates. Biomaterials, 2008, 29, 4045-4055.	5.7	503
3	Methodology for the Immobilization of Enzymes onto Mesoporous Materials. Journal of Physical Chemistry B, 2005, 109, 19496-19506.	1.2	176
4	Injectable in situ cross-linking hydrogels for local antifungal therapy. Biomaterials, 2010, 31, 1444-1452.	5.7	126
5	A Nanoporous Reactor for Efficient Proteolysis. Chemistry - A European Journal, 2008, 14, 151-157.	1.7	76
6	Tuning the strength and swelling of an injectable polysaccharide hydrogel and the subsequent release of a broad spectrum bacteriocin, nisin A. Journal of Materials Chemistry B, 2020, 8, 4029-4038.	2.9	49
7	Preparation and characterization of amorphous ciprofloxacin-amino acid salts. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 121, 73-89.	2.0	38
8	Investigation of the Solid-State Polymorphic Transformations of Piracetam. Crystal Growth and Design, 2012, 12, 6223-6233.	1.4	37
9	Thermodynamics of fenofibrate and solubility in pure organic solvents. Fluid Phase Equilibria, 2014, 367, 143-150.	1.4	36
10	Mesoporous matrices for the delivery of the broad spectrum bacteriocin, nisin A. Journal of Colloid and Interface Science, 2019, 537, 396-406.	5 . 0	33
11	Adsorption and Activity of a Domoic Acid Binding Antibody Fragment on Mesoporous Silicates. Journal of Physical Chemistry B, 2006, 110, 18703-18709.	1.2	31
12	Modification of the zeta potential of montmorillonite to achieve high active pharmaceutical ingredient nanoparticle loading and stabilization with optimum dissolution properties. Colloids and Surfaces B: Biointerfaces, 2020, 193, 111120.	2. 5	28
13	Investigation of the Particle Growth of Fenofibrate following Antisolvent Precipitation and Freeze–Drying. Crystal Growth and Design, 2015, 15, 5213-5222.	1.4	24
14	Investigation into the Solid and Solution Properties of Known and Novel Polymorphs of the Antimicrobial Molecule Clofazimine. Crystal Growth and Design, 2016, 16, 7240-7250.	1.4	21
15	Pre-formulation and delivery strategies for the development of bacteriocins as next generation antibiotics. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 165, 149-163.	2.0	21
16	Stepwise Use of Additives for Improved Control over Formation and Stability of Mefenamic Acid Nanocrystals Produced by Antisolvent Precipitation. Crystal Growth and Design, 2017, 17, 454-466.	1.4	20
17	Role of Biorelevant Dissolution Media in the Selection of Optimal Salt Forms of Oral Drugs: Maximizing the Gastrointestinal Solubility and in Vitro Activity of the Antimicrobial Molecule, Clofazimine. ACS Omega, 2017, 2, 8969-8981.	1.6	20
18	Protecting bactofencin A to enable its antimicrobial activity using mesoporous matrices. International Journal of Pharmaceutics, 2019, 558, 9-17.	2.6	20

#	Article	IF	CITATIONS
19	Size and Shape Control of Micron-Sized Salicylic Acid Crystals during Antisolvent Crystallization. Organic Process Research and Development, 2017, 21, 1732-1740.	1.3	19
20	Dependence of Heterogeneous Nucleation on Hydrogen Bonding Lifetime and Complementarity. Crystal Growth and Design, 2018, 18, 7158-7172.	1.4	19
21	Experimental Study on the Influence of Excipients on the Heterogeneous Crystallization and Dissolution Properties of an Active Pharmaceutical Ingredient. Crystal Growth and Design, 2018, 18, 338-350.	1.4	18
22	Modulating the release of pharmaceuticals from lipid cubic phases using a lipase inhibitor. Journal of Colloid and Interface Science, 2020, 573, 176-192.	5.0	17
23	Carrier particle design for stabilization and isolation of drug nanoparticles. International Journal of Pharmaceutics, 2017, 518, 111-118.	2.6	15
24	Promotion of Mefenamic Acid Nucleation by a Surfactant Additive, Docusate Sodium. Crystal Growth and Design, 2019, 19, 591-603.	1.4	15
25	Heterogeneous Crystallization of Fenofibrate onto Pharmaceutical Excipients. Crystal Growth and Design, 2018, 18, 2151-2164.	1.4	14
26	Carrier particle mediated stabilization and isolation of valsartan nanoparticles. Colloids and Surfaces B: Biointerfaces, 2019, 175, 554-563.	2.5	14
27	Influence of Process Parameters on the Heterogeneous Nucleation of Active Pharmaceutical Ingredients onto Excipients. Organic Process Research and Development, 2017, 21, 559-570.	1.3	13
28	The heterogeneous crystallization of a novel solvate of clozapine base in the presence of excipients. CrystEngComm, 2018, 20, 4370-4382.	1.3	13
29	Recyclable SERS substrates based on Fe ₂ O ₃ –Ag hybrid hollow microspheres with crumpled surfaces. New Journal of Chemistry, 2016, 40, 5238-5244.	1.4	11
30	Delivery of a hydrophobic drug into the lower gastrointestinal system via an endogenous enzyme-mediated carrier mechanism: An in vitro study. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 133, 12-19.	2.0	11
31	Enhancement and restriction of chain motion in polymer networks. International Journal of Pharmaceutics, 2012, 430, 34-41.	2.6	10
32	Pharmaceutical design of a delivery system for the bacteriocin lacticin 3147. Drug Delivery and Translational Research, 2021, 11, 1735-1751.	3.0	10
33	Candidates for smart cardiovascular medical device coatings: A comparative study with endothelial and smooth muscle cells. European Journal of Pharmacology, 2021, 910, 174490.	1.7	7
34	Investigating the effects of amphipathic gastrointestinal compounds on the solution behaviour of salt and free base forms of clofazimine: An in vitro evaluation. International Journal of Pharmaceutics, 2018, 552, 180-192.	2.6	6
35	Drug Loading and Dissolution Properties of Dalcetrapib–Montmorillonite Nanocomposite Microparticles. Organic Process Research and Development, 2020, 24, 977-987.	1.3	6
36	Drug delivery for fighting infectious diseases: a global perspective. Drug Delivery and Translational Research, 2021, 11, 1316-1322.	3.0	6

3

#	Article	IF	CITATIONS
37	Synergistic antimicrobial interactions of nisin A with biopolymers and solubilising agents for oral drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 171, 29-38.	2.0	6
38	Single versus double occupancy solid lipid nanoparticles for delivery of the dual-acting bacteriocin, lacticin 3147. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 176, 199-210.	2.0	6
39	Proteins in Mesoporous Silicates. ACS Symposium Series, 2008, , 49-60.	0.5	5
40	The impact of endogenous gastrointestinal molecules on the dissolution and precipitation of orally delivered hydrophobic APIs. Expert Opinion on Drug Delivery, 2020, 17, 677-688.	2.4	5
41	The impact of varying dextran oxidation levels on the inhibitory activity of a bacteriocin loaded injectable hydrogel. Drug Delivery and Translational Research, 2023, 13, 308-319.	3.0	5
42	Overcoming the Common Ion Effect for Weakly Basic Drugs: Inhibiting the Crystallization of Clofazimine Hydrochloride in Simulated Gastrointestinal Media. Crystal Growth and Design, 2019, 19, 1599-1609.	1.4	4
43	Citric acid functionalized nitinol stent surface promotes endothelial cell healing. Journal of Biomedical Materials Research - Part A, 2021, 109, 1549-1559.	2.1	4
44	Preparation, stabilisation, isolation and tableting of valsartan nanoparticles using a semi-continuous carrier particle mediated process. International Journal of Pharmaceutics, 2021, 597, 120199.	2.6	4
45	Lipid Cubic Systems for Sustained and Controlled Delivery of Antihistamine Drugs. Molecular Pharmaceutics, 2021, 18, 3777-3794.	2.3	4
46	Balanced lipase interactions for degradation-controlled paclitaxel release from lipid cubic phase formulations. Journal of Colloid and Interface Science, 2022, 607, 978-991.	5.0	4
47	NUIG4: A biocompatible pcu metal–organic framework with an exceptional doxorubicin encapsulation capacity. Journal of Materials Chemistry B, 2022, 10, 1378-1385.	2.9	4
48	The influence of poly(allylamine hydrochloride) hydrogel crosslinking density on its thermal and phosphate binding properties. International Journal of Pharmaceutics, 2022, 621, 121806.	2.6	3
49	Long acting injectables for therapeutic proteins. Colloids and Surfaces B: Biointerfaces, 2022, 217, 112644.	2.5	3
50	Stent conditioned media for in vitro evaluation of hydrophobic stent coatings. Toxicology in Vitro, 2021, 76, 105212.	1.1	1